CHU Montreal

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Sickle cell disease2 trials
• Head and neck cancer1 trial

Phase

• Phase 21 trial
• Phase 2/31 trial
• Phase 31 trial

Status

• Active, not recruiting2 trials
• Terminated1 trial

Lead sponsor

• Agios Pharmaceuticals, Inc.2 trials
• EMD Serono Research & Development Institute, Inc.1 trial

Running trials

• Active, not recruiting

  A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

  NCT06924970· Phase 2· Agios Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

  NCT05031780· Phase 2/3· Agios Pharmaceuticals, Inc.· Source

Closed trials

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source